Case study 04
Next Generation Targeted Lipid Nanoparticles (LNP)
Athebody® DARPin is an ideal modality enable specific delivery of LNP
Pubished partnership: Acuitas
Lipid nanoparticles (LNPs)
- mRNA-LNP-based therapeutics were boosted by the success of COVID-19 mRNA vaccines.
- LNP became one of the most advanced, clinically approved non-viral delivery systems for nucleic-acid therapeutics and small molecules.
- Since LNPs naturally accumulate in liver cells upon intravenous administration, there is an urgent need to enhance uptake by target cell types.
Enhance uptake by target cells
- Decorating the LNP surface with Athebody® DARPins as targeting ligand allows selective delivery and directed uptake of mRNA/DNA cargo to cell types and tissue of choice.
- Athebody® building blocks are ideal binding moieties for targeted LNPs due to their compatibility with harsh chemical conditions and efficient chemical conjugation in a site-specific manner.
What is your project?
We are looking forward to hearing your ideas how Athebody® DARPins can enable your projects and how you like to access it.